Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease (F-IBDQ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01891214
Recruitment Status : Completed
First Posted : July 3, 2013
Last Update Posted : February 15, 2017
Sponsor:
Information provided by (Responsible Party):
Rennes University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of the study is to develop a validated French version of the IBDQ in a cohort of patients suffering from Inflammatory bowel diseases, namely Crohn's disease and Ulcerative Colitis.

Condition or disease Intervention/treatment
Ulcerative Colitis Crohn's Disease Other: Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)

Detailed Description:
Importance of measuring subjective aspects of the patient's health, often referred to as quality of life (QoL), become increasingly recognized and integrated into healthcare. For this purpose, The Inflammatory Bowel Disease Questionnaire (IBDQ) is a widely used questionnaire for QoL assessment specific for patients who suffer from inflammatory bowel diseases. However, the IBDQ was originally developed in a cohort of Canadian patients in English language. Since QoL is impacted by underlying cultural trends, any translation of the IBDQ should be reassessed in relation to its validity, reliability, and sensitivity to detect change in the new language and cultural context. While the linguistic French translation of the original IBDQ has been validated, the French IBDQ has never been tested adequately on a French cohort of patient that we aim to perform.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease
Actual Study Start Date : December 2013
Actual Primary Completion Date : April 2016
Actual Study Completion Date : January 2017

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Ulcerative Colitis and Crohn's Disease Other: Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Internal validity, scale F-IBDQ [ Time Frame: Day1 and Month4 ]
    Chronbach's alpha coefficient, measured at the first visit and at the second visit.

  2. External validity, questionnaire SF36 [ Time Frame: Day1 and Month4 ]
    Correlation with the French validated SF-36 and disease activity indexes (Harvey Bradshaw index for Crohn's disease and Simple Colitis Activity Index for ulcerative colitis, measured at the first visit and at the second visit.

  3. Discriminant ability, disease activity indexes [ Time Frame: Day1 and Month4 ]
    Correlation with disease activity indexes, measured at the first visit and at the second visit.

  4. Reliability, disease outcomes [ Time Frame: Day1 and Month4 ]
    Correlation with disease outcomes, measured at the first visit and at the second visit.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient with definite diagnosis of UC or CD for at least 6 months
Criteria

Inclusion Criteria:

  • men and women ≥ 18 years of age,
  • patient with definite diagnosis of UC or CD for at least 6 months

Exclusion Criteria:

  • adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty
  • inability to comprehend or complete the self-administered questionnaire
  • psychiatric diagnosis that prevents participation (many pts will have anxiety or depression and should not be excluded)
  • stoma
  • malignancy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01891214


Locations
Layout table for location information
France
CHRU de Nancy
Nancy, France
Service des Maladies de l'Appareil Digestif, Hôpital de Pontchaillou, 2 rue Henri Le Guilloux
Rennes, France, 35033
Sponsors and Collaborators
Rennes University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Guillaume Bouguen Rennes University Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Rennes University Hospital
ClinicalTrials.gov Identifier: NCT01891214    
Other Study ID Numbers: 2013-A00144-41
LOC/12-17 Bouguen F-IBDQ ( Other Identifier: Rennes University Hospital )
First Posted: July 3, 2013    Key Record Dates
Last Update Posted: February 15, 2017
Last Verified: February 2017
Keywords provided by Rennes University Hospital:
Inflammatory bowel diseases
Inflammatory Bowel Disease Questionnaire (IBDQ)
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Colitis
Colitis, Ulcerative
Intestinal Diseases
Inflammatory Bowel Diseases
Ulcer
 Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Pathologic Processes